Valeant enters licensing agreement with Norgine

A licensing agreement with Norgine B.V. will give Valeant Pharmaceuticals the rights to the development and commercialization of NER1006 Powder for Oral Solution in the United States and Canada.
"We are excited to partner with Norgine to bring an innovative treatment to the patients that need it most," Valeant Chairman and CEO Joseph Papa said. "To date, NER1006's clinical results have been positive and it is an excellent strategic fit with the Salix portfolio that will enhance our gastrointestinal business."
Papa said the agreement reflects Valeant's commitment to bolstering research and development and its commercial offerings.
"We are extremely pleased to enter into this agreement with Valeant and build upon our successful partnership for MOVIPREP,” Norgine CEO Peter Stein said. “Valeant has an established presence in gastroenterology in the U.S. and Canada and a strong portfolio of products in this therapy area. As a European specialist pharma company, Norgine is entirely focused upon the development and commercialization of products in Europe. Valeant is therefore an excellent choice as our partner for the launch of NER1006 in the U.S. and Canada."